Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AND014
MIFTS: 44

Androgenic Alopecia

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Androgenic Alopecia

About this section

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia 12 15
Androgenetic Alopecia 12 74
Alopecia Androgenetica, Male Pattern Baldness 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0050801
ICD10 34 L64
UMLS 74 C0162311
Sources

Summaries for Androgenic Alopecia

About this section
Disease Ontology : 12 An alopecia that is characterized by M-shaped hair line recession and thinning of hair at the crown of the head in males.

MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and alopecia. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Regulation of Androgen receptor activity. The drugs Finasteride and Minoxidil have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and skin, and related phenotype is reproductive system.

Wikipedia : 77 Pattern hair loss, known as male-pattern hair loss (MPHL) when it affects males and female-pattern hair... more...

Sources

Related Diseases for Androgenic Alopecia

About this section

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 32.0 AR CYP19A1 SHBG SRD5A2
2 alopecia 31.2 AR EDA2R HR SHBG
3 sexual disorder 30.6 KLK3 PRL SHBG
4 impotence 30.3 KLK3 PRL SHBG
5 polycystic ovary syndrome 30.1 CYP19A1 PRL SHBG
6 hyperandrogenism 29.9 CYP19A1 PRL SHBG
7 prostatic hyperplasia, benign 29.8 AR KLK3 SHBG SRD5A2
8 prostate cancer 29.4 AR CYP19A1 KLK3 SHBG SRD5A2
9 marie unna congenital hypotrichosis 11.4
10 hypotrichosis 1 11.3
11 hypotrichosis simplex 11.3
12 47, xxy 10.4 AR SHBG
13 postmenopausal atrophic vaginitis 10.3 AR SHBG
14 neurofibromatosis, type ii 10.3
15 lichen planopilaris 10.3
16 hypoactive sexual desire disorder 10.3 CYP19A1 SHBG
17 nodular prostate 10.3 AR KLK3
18 sebaceous gland disease 10.3 AR SHBG
19 pelvic varices 10.3 PRL SHBG
20 arteries, anomalies of 10.3
21 coronary artery anomaly 10.3
22 diffuse alopecia areata 10.3
23 heart disease 10.3
24 frontal fibrosing alopecia 10.3
25 transsexualism 10.3 AR CYP19A1
26 gender identity disorder 10.3 AR CYP19A1
27 withdrawal disorder 10.2 AR KLK3
28 premenstrual tension 10.2 PRL SHBG
29 male reproductive organ benign neoplasm 10.2 CYP19A1 KLK3
30 prostate cancer, hereditary, 8 10.2
31 prostate cancer, hereditary, 6 10.2
32 hermaphroditism 10.2 AR SRD5A2
33 cystitis cystica 10.2 AR KLK3
34 mammographic density 10.2 CYP19A1 PRL
35 coronary heart disease 1 10.2
36 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.2
37 dermatitis 10.2
38 psoriasis 10.2
39 depression 10.2
40 male reproductive organ cancer 10.2 AR KLK3 SHBG
41 male reproductive system disease 10.2 AR KLK3 SHBG
42 oligospermia 10.2 AR PRL
43 androgen insensitivity, partial 10.2 AR CYP19A1 SHBG
44 complete androgen insensitivity syndrome 10.2 AR CYP19A1 SHBG
45 pseudovaginal perineoscrotal hypospadias 10.1 AR SRD5A2
46 alopecia areata 10.1
47 cryptorchidism, unilateral or bilateral 10.1 AR CYP19A1 SHBG
48 hypothyroidism, central, and testicular enlargement 10.1 CYP19A1 PRL
49 estrogen excess 10.1 CYP19A1 PRL SHBG
50 prostatic hypertrophy 10.1 AR CYP19A1 KLK3

Graphical network of the top 20 diseases related to Androgenic Alopecia:



Diseases related to Androgenic Alopecia
Sources

Symptoms & Phenotypes for Androgenic Alopecia

About this section

MGI Mouse Phenotypes related to Androgenic Alopecia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.1 AR CYP19A1 HR LPP PRL SRD5A2
Sources

Drugs & Therapeutics for Androgenic Alopecia

About this section

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
2
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 38304-91-5 4201
3 Hormones Phase 4,Phase 3,Phase 1,Phase 2
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
5 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
6 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
7 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
8 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
9 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 6918296 152945
11 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
13
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
14
Bimatoprost Approved, Investigational Phase 2,Phase 1 155206-00-1 5311027
15
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
16
Vitamin C Approved, Nutraceutical Phase 1, Phase 2,Phase 2 50-81-7 54670067 5785
17
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
18 HIV Protease Inhibitors Phase 2
19
protease inhibitors Phase 2
20 Proteasome Inhibitors Phase 2
21 Radiation-Protective Agents Phase 2
22 Protective Agents Phase 2,Phase 1
23 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
24 Antiviral Agents Phase 2
25 Anti-Infective Agents Phase 2,Not Applicable
26 Immunologic Factors Phase 2
27 Adjuvants, Immunologic Phase 2
28 Free Radical Scavengers Phase 1, Phase 2
29 Anti-Asthmatic Agents Phase 1, Phase 2
30 Bronchodilator Agents Phase 1, Phase 2
31 Peripheral Nervous System Agents Phase 1, Phase 2
32 Autonomic Agents Phase 1, Phase 2
33 Antioxidants Phase 1, Phase 2
34 Neurotransmitter Agents Phase 1, Phase 2,Phase 2
35 Respiratory System Agents Phase 1, Phase 2
36 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
37 Mitogens Phase 1, Phase 2,Not Applicable
38 Androgens Phase 2,Phase 1
39 Cholinergic Agents Phase 2
40 abobotulinumtoxinA Phase 2
41 Acetylcholine Release Inhibitors Phase 2
42 Botulinum Toxins Phase 2
43 Botulinum Toxins, Type A Phase 2
44 Ophthalmic Solutions Phase 2
45 Antimanic Agents Phase 2
46 Psychotropic Drugs Phase 2
47 Tranquilizing Agents Phase 2
48 Central Nervous System Depressants Phase 2
49 Anticonvulsants Phase 2
50 GABA Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
3 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
4 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
5 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
6 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
7 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
8 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
9 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
10 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
11 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
12 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
13 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
14 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
15 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
16 A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
17 Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Male Pattern Hair Loss Active, not recruiting NCT03753113 Phase 3 Topical Minoxidil 5%
18 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Unknown status NCT01501617 Phase 1, Phase 2
19 Treatment of Androgenetic Alopecia in Males With Theradomeâ„¢ LH80 PRO Unknown status NCT02528552 Phase 2
20 A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Unknown status NCT01643629 Phase 1, Phase 2
21 Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
22 Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
23 Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
24 Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
25 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
26 A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
27 Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia Completed NCT01286649 Phase 1, Phase 2
28 A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
29 A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
30 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
31 Treatment of Male Pattern Baldness With Botulinum Toxin Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
32 Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
33 Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Completed NCT02150187 Phase 2
34 Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
35 A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
36 Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
37 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
38 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
39 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed NCT02170662 Phase 2 Bimatoprost;Placebo
40 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia Completed NCT02503852 Phase 2
41 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) Completed NCT01451125 Phase 2
42 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) Completed NCT01669746 Phase 2
43 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) Completed NCT01451190 Phase 2
44 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) Completed NCT01451177 Phase 2
45 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) Completed NCT01451151 Phase 2
46 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) Completed NCT01451138 Phase 2
47 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) Completed NCT01451112 Phase 2
48 A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
49 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) Completed NCT01451073 Phase 2
50 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) Completed NCT01451047 Phase 2

Search NIH Clinical Center for Androgenic Alopecia

Sources

Genetic Tests for Androgenic Alopecia

About this section
Sources

Anatomical Context for Androgenic Alopecia

About this section

MalaCards organs/tissues related to Androgenic Alopecia:

42
Prostate, Testes, Skin, Heart, Ovary, Breast, Bone
Sources

Publications for Androgenic Alopecia

About this section

Articles related to Androgenic Alopecia:

(show top 50) (show all 772)
# Title Authors Year
1
Types of hairline recession in androgenetic alopecia and perceptions of aging in Asian males. ( 30888056 )
2019
2
The effect of platelet-rich plasma injection in the treatment of androgenetic alopecia. ( 30895745 )
2019
3
Finasteride and Androgenic Alopecia; from Therapeutic Options to Medical Implications. ( 30897009 )
2019
4
Androgenetic alopecia and microneedling: Every needling is not microneedling. ( 30905794 )
2019
5
Development of finasteride polymer microspheres for systemic application in androgenic alopecia. ( 30942390 )
2019
6
Platelet-Rich Plasma and Micrografts Enriched with Autologous Human Follicle Mesenchymal Stem Cells Improve Hair Re-Growth in Androgenetic Alopecia. Biomolecular Pathway Analysis and Clinical Evaluation. ( 30965624 )
2019
7
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. ( 30974011 )
2019
8
An overview of herbal alternatives in androgenetic alopecia. ( 30980598 )
2019
9
A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. ( 30982177 )
2019
10
Comparative Study between Mesotherapy and Topical 5% Minoxidil by Dermoscopic Evaluation for Androgenic Alopecia in Male: A Randomized Controlled Trial. ( 31007474 )
2019
11
A Study to Compare the Efficacy of Platelet-rich Plasma and Minoxidil Therapy for the Treatment of Androgenetic Alopecia. ( 31007475 )
2019
12
Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia and lower urinary tract symptoms. ( 31011438 )
2019
13
The Higher Number and Longer Duration of Kenogen Hairs Are the Main Cause of the Hair Rarefaction in Androgenetic Alopecia. ( 31049336 )
2019
14
Microbiome in the hair follicle of androgenetic alopecia patients. ( 31050675 )
2019
15
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. ( 31054970 )
2019
16
Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study. ( 31062723 )
2019
17
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. ( 31066492 )
2019
18
Hair distribution width - a novel trichoscopy parameter for hair miniaturization in androgenetic alopecia. ( 31066933 )
2019
19
Advances in Regenerative Stem Cell Therapy in Androgenic Alopecia and Hair Loss: Wnt pathway, Growth-Factor, and Mesenchymal Stem Cell Signaling Impact Analysis on Cell Growth and Hair Follicle Development. ( 31100937 )
2019
20
Dickkopf-1 Expression in Androgenetic Alopecia and Alopecia Areata in Male Patients. ( 30640755 )
2019
21
Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review. ( 30652260 )
2019
22
PLATELET RICH PLASMA IN ANDROGENETIC ALOPECIA: A SYSTEMATIC REVIEW. ( 30667146 )
2019
23
Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results. ( 30671883 )
2019
24
Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. ( 30706177 )
2019
25
Serum biotin and zinc in male androgenetic alopecia. ( 30714301 )
2019
26
Prostaglandins in androgenetic alopecia in 12 men and four female. ( 30730082 )
2019
27
Clinical Profile of Androgenic Alopecia and Its Association with Cardiovascular Risk Factors. ( 30745630 )
2019
28
The Association of Metabolic Syndrome and Insulin Resistance in Early-Onset Androgenetic Alopecia in Males: A Case-Control Study. ( 30745631 )
2019
29
Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. ( 30809579 )
2019
30
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. ( 30830894 )
2019
31
Finasteride for androgenetic alopecia is not associated with sexual dysfunction: A survey-based, single-center, controlled study. ( 30835851 )
2019
32
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. ( 30843235 )
2019
33
The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. ( 30863034 )
2019
34
Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma - with or without concurrent bimatoprost and/or minoxidil. ( 30865404 )
2019
35
Letter in response to "The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia". ( 30880717 )
2019
36
Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. ( 30882509 )
2019
37
HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. ( 30394586 )
2019
38
Acne development in male androgenetic alopecia. ( 30499125 )
2019
39
Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. ( 30536893 )
2019
40
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( 30206635 )
2019
41
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. ( 30209896 )
2019
42
Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( 30253001 )
2019
43
Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. ( 30301703 )
2019
44
Distinguishing immunohistochemical features of alopecia areata from androgenic alopecia. ( 29790258 )
2019
45
Insights into Male Androgenetic Alopecia: Differential Gene Expression Profiling of Plucked Hair Follicles and Integration with Genetic Data. ( 30009830 )
2019
46
Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study. ( 29659116 )
2019
47
Platelet-rich plasma on female androgenetic alopecia: Tested on 10 patients. ( 29707872 )
2019
48
New-Onset Androgenic Alopecia following Human Chorionic Gonadotropic Diet and Testosterone Pellet Implantation. ( 30783337 )
2018
49
A Randomized Controlled, Single-Observer Blinded Study to Determine the Efficacy of Topical Minoxidil plus Microneedling versus Topical Minoxidil Alone in the Treatment of Androgenetic Alopecia. ( 30886475 )
2018
50
Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. ( 30376555 )
2018
Sources

Variations for Androgenic Alopecia

About this section
Sources

Expression for Androgenic Alopecia

About this section
Search GEO for disease gene expression data for Androgenic Alopecia.
Sources

Pathways for Androgenic Alopecia

About this section

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 11.3 AR KLK3 SRD5A2
2
Regulation of Androgen receptor activity 1
11.02 AR KLK3
3
FOXA1 transcription factor network 1
Show member pathways
 10.92 AR KLK3
4
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
10.81 AR CYP19A1
5
Nongenotropic Androgen signaling 1
9.88 AR SHBG
Sources

GO Terms for Androgenic Alopecia

About this section

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.63 AR EFNA3 SRD5A2
2 negative regulation of angiogenesis GO:0016525 9.5 EFNA3 KLK3 PRL
3 mammary gland development GO:0030879 9.43 CYP19A1 PRL
4 sex differentiation GO:0007548 9.4 AR SRD5A2
5 androgen metabolic process GO:0008209 9.37 CYP19A1 SRD5A2
6 regulation of systemic arterial blood pressure GO:0003073 9.26 AR KLK3
7 prostate gland growth GO:0060736 9.16 AR CYP19A1
8 female genitalia development GO:0030540 8.65 CYP19A1
9 testosterone biosynthetic process GO:0061370 8.62 CYP19A1 SRD5A2

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.96 AR SHBG
2 androgen binding GO:0005497 8.62 AR SHBG
Sources

Sources for Androgenic Alopecia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....